Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Bictegravir Sodium

FDA-approved product (tablet, oral).

Registered studies
3
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Bictegravir Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

Anti-infective classification
Neither a WHO ATC code nor an FDA pharmacologic class was found for it, so whether it is already an antimicrobial is not established. It needs review and is not counted as a repurposing candidate.

Repurposing investigation

Bictegravir Sodium reaches ≥40% AI-predicted activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae, but no WHO ATC code or FDA pharmacologic class says whether it is already an antimicrobial. It needs review, so it is not counted among the repurposing candidates.

AI-predicted activity

AI prediction · nothing measured
  • MRSA67.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli57.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae58.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis67.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

3registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Bictegravir Sodium in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-9.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-10.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-10.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Bictegravir Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission

    NCT05719441 · start 2024-08-19

    Registered record
    Registry ID
    NCT05719441
    Conditions
    Acute HIV Infection
    Interventions
    VRC07-523LS; PGT121.414.LS; Placebo; ART
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-08-19
    Completion
    2028-09-06
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute HIV Infection
    InterventionVRC07-523LS; PGT121.414.LS; Placebo; ART
    PhasePhase 2
    Registry statusRecruiting

  • Doravirine and Weight Gain in Antiretroviral Naive

    NCT05457530 · start 2022-08-01

    Registered record
    Registry ID
    NCT05457530
    Conditions
    Body Weight Changes; Human Immunodeficiency Virus; ART; Obesity; Minority Health; BMD; Metabolic Syndrome; Fasting
    Interventions
    DOR/3TC/TDF; DOR + FTC/TAF; BIC/FTC/TAF
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2022-08-01
    Completion
    2023-05-03
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBody Weight Changes; Human Immunodeficiency Virus; ART; Obesity +4 more
    InterventionDOR/3TC/TDF; DOR + FTC/TAF; BIC/FTC/TAF
    PhasePhase 3
    Registry statusWithdrawn

  • INSTI's For The Management of HIV-associated TB

    NCT04734652 · start 2022-02-18

    Registered record
    Registry ID
    NCT04734652
    Conditions
    HIV/AIDS; Tuberculosis, Pulmonary
    Interventions
    Biktarvy®; TLD- fixed-drug combination single tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2022-02-18
    Completion
    2024-08-31
    Enrolment
    122

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV/AIDS; Tuberculosis, Pulmonary
    InterventionBiktarvy®; TLD- fixed-drug combination single tablet
    PhasePhase 2
    Registry statusCompleted